



IMAGION[®]

B I O S Y S T E M S

MagSense™ Technology

A New Functional Imaging Technology for Targeted Early Detection of Cancer

AusBiotech Asian Investor Conference 2019 | ASX:IBX

DISCLAIMER



*This investor presentation (**Presentation**) has been prepared by Imagion Biosystems Limited (**Imagion** or the **Company**). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Imagion or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Imagion or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.*

This presentation is not a Prospectus and contains summary information about Imagion and its activities, which is current as at the date of this presentation. The information included in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor should consider when making an investment decision. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Imagion and the impact that different future outcomes may have on Imagion. This presentation has been prepared without taking account of any person's investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, make their own assessment of the information and seek legal, financial, accounting and taxation advice appropriate to their jurisdiction in relation to the information and any action taken on the basis of the information. Imagion is an early stage medical technology company and has so far has not conducted research in human subjects.

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. Unless required by applicable law or regulation, no person (including Imagion) is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, currency, accuracy, reasonableness or completeness of the information contained herein. Neither Imagion nor any other person (including its shareholders, directors, officers and employees) accepts any liability and Imagion, its shareholders, its related bodies corporate and their respective directors, officers and employees, to the maximum extent permitted by law, expressly disclaim all liabilities for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current expectations concerning, among other things, Imagion's results of operations, financial condition, performance, prospects, growth, strategies and the industry in which Imagion operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors, many of which are beyond the control of Imagion. Imagion cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition, performance, prospects, growth or opportunities and the development of the industry in which Imagion operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, Imagion does not guarantee any particular rate of return or the performance of Imagion nor does it guarantee the repayment or maintenance of capital or any particular tax treatment. Investors should note that past performance may not be indicative of results or developments in future periods and cannot be relied upon as an indicator of (and provides no guidance as to) Imagion's future performance. Imagion, its related bodies corporate and each of their respective directors, officers and employees and advisers expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in Imagion's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.


This presentation and any materials distributed in connection with this presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe any such restrictions.

CANCER DIAGNOSTICS MARKET




CANCER DIAGNOSTICS - \$100B MARKET



* Source: Transparency Market Research – Global Cancer Diagnostics Market 2014-2020

5- YEAR SURVIVAL RATE DEPENDING ON EARLY OR LATE DIAGNOSIS:



* Source: SEER Cancer statistics, National Cancer Institute, 2013

Cancer diagnostics is a \$100 billion market growing at a CAGR of >7%* with **imaging techniques accounting for the largest portion.**

Cancer continues to be one of the leading causes of mortality globally despite technical advances in science & medicine made in the last 150 years.

THE CONSENSUS WITHIN THE MEDICAL COMMUNITY & SUPPORTED BY THE SEER CANCER STATISTICS IS THAT MORE LIVES COULD BE SAVED IF CANCER COULD BE DETECTED EARLIER.

UNMET MEDICAL NEED



Current technologies have significant drawbacks

- | No new medical imaging technology in last 50 years
- | Current methods identify a “region of interest” but cannot differentiate benign from malignant tumors
- | X-rays & PET scans expose patient to ionizing radiation
- | Requires an invasive & risky biopsy procedures to confirm diagnosis



MagSense Technology

SAFE

Non-invasive method able to minimize need for surgical or biopsy procedures

No radio-isotopes are used. Particles are metabolized & excreted by normal processes

EFFECTIVE


More sensitive than current clinical imaging guidelines

Functional imaging method able to identify specific tumors

HOW MAGSENSE NANOPARTICLES WORK



High sensitivity cancer specific detection



- The cancer specific antibodies on the nanoparticles cause the particles to stick to the tumour cells
- All nanoparticles demagnetize or “relax” after exposure to a low magnetic field
- A nanoparticle attached to a bio-marked cancer cell will relax more slowly than particles in circulation
- Imagination’s ultra-sensitive detectors are able to identify the presence of attached nanoparticles

LOW TECHNICAL RISK

MagSense uses already proven components & principles

NANOPARTICLE FORMULA USES **KNOWN MATERIALS**

Iron oxide is already in use as contrast agents

Antibodies are the standard for therapeutics & *in vitro* diagnostics in pathology

Safety profile of nanoparticles is low risk as confirmed by regulators (FDA)

INSTRUMENT USES **PROVEN TECHNOLOGIES**

SQUID detectors are used in MEG/MCG systems

Coils are used in MRI with much higher magnetic fields

MAGSENSE WILL **NOT BE REGULATED AS A DRUG**

Clinical studies requiring fewer patients, saving cost

Patients will not require long-term monitoring



Path to First in Human



- GLP Toxicology Study (in process)
- IDE submission to FDA for Medical Device Early Feasibility Study
- GMP manufacturing of nanoparticle formulation for FIH study
- IRB submission at MD Anderson Cancer Center small First-in-Human study
 - 10-20 patient study
 - Patient safety
 - Target specificity

BUSINESS MODEL



Small capital investment for customers & proprietary consumable drive growth & profitability

PRINTER / INK

- MagSense includes the measuring instrument & consumable formulation **unique in the medical imaging market**
- Revenue & profits driven by high gross margin consumable use on growing installed instrument base

GROWTH THROUGH APPLICATIONS


- MagSense can be applied to a wide variety of diseases, increasing revenue on the installed instruments
- Can be used at multiple points in the diagnosis & treatment of patients

MONETIZING THE TECHNOLOGY

Printer/ink revenue model will be attractive to existing imaging companies

- Imagination will receive milestone fees & royalties or revenue share

Multiple Clinical Targets



OPPORTUNITY & SHAREHOLDER VALUE

Achieving First-in-Human testing de-risks technology and opens path to future products & value



STAGING BREAST CANCER

Shortest path to clinical proof

\$500M

PRIMARY TUMOR DETECTION

Breast, prostate, lung
& ovarian

\$5B

DOCTORS OFFICE

Ubiquitous like
ultrasound

>\$10B

DETECTION & THERAPY

Nanoparticle provides
both detection &
delivery of therapy

>\$100B

Addressable Markets

INVESTMENT HIGHLIGHTS



LARGE OPPORTUNITY

\$100B cancer diagnostic market

Growing 7% annually

Medical imaging commands largest share

Under-addressed need for early diagnosis



UNIQUE TECHNOLOGY

New form of medical imaging

Molecularly specific & non-invasive

More sensitive than current methods

Protected by eight patents



COMMERCIAL STRATEGY

\$2B initial market focus

Applies to many types of cancer

Printer-ink revenue model

Potential for therapeutics & research markets



HIGHLY DE-RISKED

Technical feasibility demonstrated

Safety profile of technology vetted with FDA

Management & Board with track record bringing products to market



IMAGION
BIOSYSTEMS

IMAGION BIOSYSTEMS

www.imagionbiosystems.com